ERBB2 and cancer: We demonstrate beneficial immune cell-mediated and immunomodulatory effects of anti-HER2 IgE, especially promotion of pro-inflammatory immune phenotype shifts and “reprogramming” of the TME in HER2+ cancers, reducing immunosuppressive effects and protumoral pathways.